Status:
COMPLETED
Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)
Lead Sponsor:
Hallym University Medical Center
Conditions:
Attention Deficit Disorder With Hyperactivity
Methylphenidate
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of...
Eligibility Criteria
Inclusion
- ADHD
- Physically healthy
Exclusion
- Neurological illness
- Concurrent additional psychiatric treatment
- \< IQ 70
- Psychotic disorder
- Major mood disorder needed other psychiatric medication
- Significant suicidal ideation
- Pervasive developmental disorder
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00757029
Start Date
October 1 2005
End Date
August 1 2010
Last Update
October 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, South Korea